

5-HT₃ Receptor Antagonists: New Promising Therapeutic Agents in Diabetes and Its Complications

Reza Rahimian^{1,2}, Shahram Ejtemaei Mehr¹, Gohar Fakhfouri³, and Ahmad Reza Dehpour^{1,2}

¹ Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

² Brain and Spinal Injury Repair Research Center, Tehran University of Medical Sciences, Tehran, Iran

³ Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

The role of serotonin and its diverse serotonin (5-HT) receptors has been investigated in glucose metabolism and pathogenesis of diabetes. In rats, activation of central serotonergic system induces hyperglycemia which can be reverted by prior administration of a serotonin type 3 (5-HT₃) receptor antagonist, ondansetron, indicating the involvement of 5-HT₃ receptor subtype in this hyperglycemic effect. Of note, tropisetron, another 5-HT₃ receptor antagonist, was found to enhance the insulin release by INS-1 cells. The effect was interestingly more pronounced in the presence of serotonin at the highest concentration used (500 μM). Serotonin *per se* reduced the glucose-stimulated liberation of insulin in a concentration-dependent fashion, while tropisetron abolished this inhibition. Such observation points out the involvement of 5-HT₃ receptors in tropisetron-induced insulin secretion (1,2). The underlying mechanism concerning secretagogue action of 5-HT₃ antagonists is, however, wrapped up in obscurity as the main target for classical insulin secreting agents is inhibition of ATP sensitive potassium channels leading to Ca⁺² entry and beta cell depolarization (3). 5-HT₃ ion channel blockade, in contrast, is associated with a reduction in inward cation currents, in particular Ca⁺². We and others showed that 5-HT₃ receptor antagonist, tropisetron can inhibit calcineurin activity in neuron and lymphocytes. Interestingly although conventional calcineurin inhibitors (cyclosporine and tacrolimus) lead to hyperglycemia via calcineurin/NFAT pathway, tropisetron exerts notable anti-inflammatory properties without affecting the blood glucose levels. Alongside these promising effects 5-HT₃ receptor antagonists have potential to combating diabetes related complications such as neuropathy, memory impairment and depression (4). Ample evidence implicates the role of 5-HT₃ receptor subtype in pain and inflammation. The analgesic effect of 5-HT₃ antagonists emerges from their aptitude to inhibit the release of sensory neuropeptides which trigger the development of neurogenic inflammation (5). 5-HT₃ receptor antagonists tropisetron and ondansetron enhanced ACh release in human

cortical tissue via blocking the inhibitory effect of 5-HT. Moreover, new investigations indicate that 5-HT₃ receptor antagonists protect against beta-amyloid-induced apoptosis in cortical primary cell cultures (3). Recent researches showed that classic antidepressants are functional antagonists at 5-HT₃ receptor, and this antagonism may constitute a novel pharmacological principle of antidepressants (6).

According to vast pharmacological effects of 5-HT₃ receptor antagonists many of which have potential to be considered in attenuation diabetes complications, they can be scrutinized in diabetes research.

References

1. Carvalho F, Marcedo D, Banderia I, Maldonado I, Salles L, Azevedo MF, Rocha MA Jr, Fregoneze JB, De Castro-Silva E. Central 5-HT₃ receptor stimulation by m-CPBG increases blood glucose in rats. *Horm Metabol Res* 2002;34:55–61.
2. Heimes K, Feistel B, Verspohl EJ. Impact of the 5-HT₃ receptor channel system for insulin secretion and interaction of ginger extracts. *Eur J of Pharmacol* 2009;624:58–65.
3. Fakhfouri G, Rahimian R, Ghia JE, Khan WI, Dehpour AR. Impact of 5-HT₃ receptor antagonists on peripheral and central diseases. *Drug Discov Today* 2012;17(13-14):741-7.
4. Rahimian R, Dehpour AR, Fakhfouri G, Khorramizadeh MR., Ghia JE, Seyedabadia M, Caldarellie A, Mousavizadehf K, Forouzandehg M, Ejtemaei Mehr Sh. Tropisetron Upregulates Cannabinoid CB₁ Receptors in Cerebellar Granule Cells: Possible Involvement of Calcineurin. *Brain Res* 2011;1417:1–8.
5. Norouzi A, Fakhfouri G, Rahimian R. How Can 5-HT₃ Receptor Antagonists Exert Analgesic Properties? *Acta Med Iran* 2012;50(4):225.
6. Eisensamer B, Rammes G, Gimpl G, Shapa M, Ferrari U, Hapfelmeier G, Bondy B, Parsons C, Gilling K, Zieglgänsberger W, Holsboer F, Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT₃) receptor. *Molecul Psychiatry* 2003;8:994–1007.

Corresponding Author: Shahram Ejtemaei Mehr

Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran P.O. Box: 13145-784 Tehran, Iran
Tel: +98 21 88973652, Fax: +98 21 66402569, E-mail: ejtemam@gmail.com